Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Lipid-related markers and cardiovascular disease prediction.

Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundström J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gómez-de-la-Cámara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J.

JAMA. 2012 Jun 20;307(23):2499-506. doi: 10.1001/jama.2012.6571.

2.

Glycated hemoglobin measurement and prediction of cardiovascular disease.

Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB Sr, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J.

JAMA. 2014 Mar 26;311(12):1225-33. doi: 10.1001/jama.2014.1873.

3.
4.
6.

Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.

Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM.

JAMA. 2012 Aug 22;308(8):788-95. doi: 10.1001/jama.2012.9624.

7.

C-reactive protein, fibrinogen, and cardiovascular disease prediction.

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J.

N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477.

8.

Cardiovascular risk prediction: Can Systematic Coronary Risk Evaluation (SCORE) be improved by adding simple risk markers? Results from the Copenhagen City Heart Study.

Graversen P, Abildstrøm SZ, Jespersen L, Borglykke A, Prescott E.

Eur J Prev Cardiol. 2016 Sep;23(14):1546-56. doi: 10.1177/2047487316638201. Epub 2016 Mar 14.

PMID:
26976846
9.

Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.

Pursnani A, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, Hoffmann U.

JAMA. 2015 Jul 14;314(2):134-41. doi: 10.1001/jama.2015.7515.

10.

Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Knowlton N, Wages JA, Centola MB, Giles J, Bathon J, Quiroga C, Alaupovic P.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):993-1000. doi: 10.1002/acr.21646.

11.

Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.

Nomikos T, Panagiotakos D, Georgousopoulou E, Metaxa V, Chrysohoou C, Skoumas I, Antonopoulou S, Tousoulis D, Stefanadis C, Pitsavos C; ATTICA Study group.

Lipids Health Dis. 2015 Sep 15;14:108. doi: 10.1186/s12944-015-0101-7.

12.

Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.

Steffen BT, Guan W, Remaley AT, Paramsothy P, Heckbert SR, McClelland RL, Greenland P, Michos ED, Tsai MY.

Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):448-54. doi: 10.1161/ATVBAHA.114.304349. Epub 2014 Dec 4.

13.

Circulating gamma glutamyltransferase and prediction of cardiovascular disease.

Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP.

Atherosclerosis. 2015 Feb;238(2):356-64. doi: 10.1016/j.atherosclerosis.2014.12.045. Epub 2014 Dec 23.

PMID:
25555268
14.
15.

Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study.

Tehrani DM, Gardin JM, Yanez D, Hirsch CH, Lloyd-Jones DM, Stein PK, Wong ND.

Atherosclerosis. 2013 Dec;231(2):246-51. doi: 10.1016/j.atherosclerosis.2013.08.036. Epub 2013 Sep 5.

16.

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS.

JAMA. 2007 Aug 15;298(7):776-85.

PMID:
17699011
17.

Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.

Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, Mayr A, Witztum JL, Kiechl S.

J Am Coll Cardiol. 2012 Nov 20;60(21):2218-29. doi: 10.1016/j.jacc.2012.08.979. Epub 2012 Nov 1.

18.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

19.

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk.

Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engström G, Williams PT, Kathiresan S, Melander O, Krauss RM.

Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1975-80. doi: 10.1161/ATVBAHA.109.190405. Epub 2009 Sep 3.

Supplemental Content

Support Center